Loading
COSMO Pharmaceuticals NV
Cosmo Pharmaceuticals NV develops and manufactures therapies for gastrointestinal diseases. The Company's proprietary technology delays the delivery of the active drug mainly into the lumen of the colon. Cosmo develops treatments for inflammatory bowel diseases such as ulcerative colitis and Crohn's disease, and for colon infections.
Funding
Every round, secondary, debt facility or acquisition involving COSMO Pharmaceuticals NV that Lounge tracks, newest first.
No rounds recorded yet.
Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.
See plans →Log inKey numbers
—
0
—
—